A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to ...

The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the ...

Long-term experience using high-dose stereotactic body radiotherapy (SBRT) confirms that this highly focused, rigidly delivered, and tightly controlled radiation approach results in excellent local ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

A study published this week found that Black Medicare beneficiaries with early-stage NSCLC remain significantly less likely than White beneficiaries to receive curative treatment, largely because of ...

Please provide your email address to receive an email when new articles are posted on . Patients with central lung tumors treated with single-fraction radiation did not experience any grade 3 or ...

Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer Survival outcomes were similar, but ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT screenings for those eligible – the disease can be completely curable.

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...